In a phase 2b multicenter study evaluating the safety and efficacy of belapectin, a Gal-3 inhibitor, in patients with NASH, cirrhosis, and PH over 52 weeks, there was no significant difference in the HVPG between the belapectin and placebo groups in both 2 mg/kg arm (−0.28 vs 0.10 mmHg, p = 1.0) and 8 mg/kg arm (−0.25 vs 0.10 mmHg, p = 1.0). This evidence concerns the gene LGALS3 and metabolic dysfunction-associated steatohepatitis.